美国面临蚊媒疾病传播加剧的局面。2024年美国报告近4000例登革热病例，较过去十年平均830例增长360%1；2023年报告10例本地获得的疟疾病例，为20年来首次1。尽管美国已掌握通过基因工程或沃尔巴克菌技术消除蚊媒疾病的手段，但过时的监管框架导致这些防控技术的商业化部署陷入长期延误。
两种主要防控技术已在国际试验中显示显著效果。Oxitec公司开发的基因工程蚊子在开曼群岛试验中将蚊子种群减少80%，在巴西Juazeiro的试验中减少约95%1。采用沃尔巴克菌技术的蚊子在新加坡随机试验中使种群减少85%，登革热感染减少约70%1。然而，审批进程严重滞后。Oxitec公司2010年首次申请FDA批准，历经10年才在2020年获得EPA实验许可1。MosquitoMate公司成为首个获批的活蚊生物农药，于2024年4月获得首个全国商业注册1。Google的Debug项目已请求EPA批准在加州和佛州释放6400万只沃尔巴克菌蚊子1。
监管体系的陈旧是延误的根本原因。当前生物技术监管基础源自1986年《协调框架》，自1980年代以来未有重大新监管法规1。拜登政府在2022年发布行政令要求解决监管不确定性，但该命令在2025年3月被特朗普政府撤销1。
The United States possesses proven technological capabilities to eliminate mosquito-borne diseases through genetic engineering and Wolbachia bacterial techniques, yet regulatory delays spanning over a decade have prevented their deployment 1. In 2024, the country reported nearly 4,000 dengue fever cases, a 360 percent increase from the ten-year average of 830 cases 1, while 2023 marked the first locally acquired malaria cases in twenty years with ten reported infections 1.
Two principal approaches have demonstrated effectiveness in trials. Oxitec's genetically modified mosquitoes reduced populations by 80 percent in the Cayman Islands and approximately 95 percent in Juazeiro, Brazil 1. Wolbachia-infected mosquitoes proved similarly promising, achieving an 85 percent population reduction in a Singapore randomized trial while cutting dengue infections by roughly 70 percent 1. Despite these results, Oxitec waited a decade between its initial 2010 FDA application and its 2020 EPA experimental permit approval 1. MosquitoMate became the first commercially approved living mosquito biopesticide following its April 2024 national registration 1. Google's Debug project has requested EPA authorization to release 64 million Wolbachia mosquitoes across California and Florida beginning June 2026 1.
The regulatory impasse stems from outdated frameworks. The 1986 Coordinated Framework remains the foundation for biotechnology oversight, with no major regulatory reforms enacted since the 1980s 1. President Biden's 2022 executive order aimed to address this regulatory uncertainty, but President Trump rescinded the directive in March 2025 1.
评论
还没有评论，欢迎留下第一条。